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Abstract In this study we report that protein kinase C j (PKC
j), one of the atypical isoforms of the PKC family located
predominantly in cytosol, is redistributed by C2-ceramide
treatment in isolated hepatocytes. PKC j increased in membrane
and nuclear fractions after 30 min of treatment with C2-ceramide
in a dose- and time-dependent manner. The action of C2-
ceramide was inhibited by wortmannin and LY 294002,
indicating that C2-ceramide-induced PKC j increase in both
nucleus and membrane fractions is mediated by phosphatidyl-
inositol 3-kinase (PI3-kinase) activation. In addition, a sig-
nificant translocation of PI3-kinase to the nucleus was observed
after C2-ceramide treatment. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Sphingolipids are found in all eukaryotic cells, where they
are primarily components of the plasma membrane [1]. Evi-
dence has emerged during the last few years that sphingolipid
metabolites such as ceramide, sphingosine and sphingosine-1-
phosphate play an important role as intracellular signaling
molecules for a variety of di¡erent targets [2]. In rat hepato-
cytes, sphingosylphosphorylcholine activates phospholipase C
(PLC) and inhibits adenylyl cyclase [3], and a role for the
sphingomyelin pathway in liver regeneration has been pro-
posed [4].
Although the intracellular distribution of protein kinase C
(PKC) isoforms varies among tissues and cells, and no general
pattern can be established, they are located in their inactive
state in cytosol and they translocate, upon stimulation to the
plasma membrane and/or nucleus [5]. The sphingolipid deriv-
atives, originally proposed as negative regulators of PKC [6],
may modulate the activity of di¡erent PKC isoforms. Thus,
PKC j may be a direct target for ceramide stimulation [7,8].
Besides, it has been shown that ceramides selectively inhibit
the PKC K [9] and stimulate autophosphorylation of PKC L
leading to its proteolysis [10]. On the other hand, the presence
and function of sphingolipid derivatives in nuclei have been
described in a number of papers, e.g. the involvement of
sphingolipid concentration in DNA stabilization [11] and
the presence of sphingomyelinase activity in rat liver nuclei
[12]. More recently, we have described an increase in calcium
concentration mediated by sphingolipids in isolated rat liver
nuclei [13]. All these results suggest a potential role of this
class of lipids in nuclear functions.
Some evidence has revealed that the activity of phosphati-
dylinositol 3-kinase (PI3-kinase) was increased by sphingo-
sine-1-phosphate [14] and C2-ceramide [15]. The enzyme,
composed of an 85 kDa regulatory subunit and a 110 kDa
catalytic subunit, phosphorylates the 3P position in the inositol
ring of phosphoinositides, which in turn act as second mes-
senger [16]. Recent work has revealed the existence of cross-
talk between PI3-kinase and PLC^PKC signaling. Thus, the
activity of PLC is enhanced by lipid products of PI3-kinase
[17^19]. Receptors coupled to the inhibitory G protein Gi,
such as that for lysophosphatidic acid, have been shown to
activate the PKC j isoform through PI3-kinase activation
[20,21]. Moreover, the involvement of PI3-kinase in nuclear
translocation of PKC j has been suggested [22]. The fact that
the nuclear PI3-kinase exists in both membranes and intra-
nuclear locations suggests that it plays a diverse role in the
regulation of nuclear functions [23], and that nuclear PI3-ki-
nase and its lipid products may provide a link for the com-
munication between cytosolic and nuclear signaling pathways.
Here we study the action of C2-ceramide on the transloca-
tion of PKC j isoform to nucleus and the involvement of PI3-
kinase activation in isolated hepatocytes.
2. Materials and methods
2.1. Materials
C2-ceramide was obtained from ICN Biomedicals Inc. LY 294002,
wortmannin, RNase A, DNase I, PI and protease inhibitors were
obtained from Sigma. Collagenase was obtained from Boehringer
Mannheim. [32P]ATP (185 TBq/mmol) was from Amersham Iberica
S.A. Nitrocellulose ¢lters were purchased from SchleicherpSchuell.
Protein-A Sepharose and ECL kit were obtained from Amersham
Pharmacia Biotech. Anti-phosphotyrosine antibody (PY20), anti-
mouse and anti-rabbit IgGs were purchased from Transduction Lab-
oratories. Anti-PKC j antibody was obtained from Santa Cruz Bio-
technology.
2.2. Isolation of rat hepatocytes
All procedures followed the guidelines of the Institutional Animal
Care and Use Committee. The hepatocytes were isolated from male
Wistar rats as described by Berry et al. [24]. Brie£y, rats were anaes-
thetized with sodium pentobarbital (10 mg/100 g body weight). The
liver was perfused ¢rst through the portal vein with Ca2-free Krebs
Henseleit (11.7 mM NaCl, 4.6 mM KCl, 1.17 mM MgSO4, 1.15 mM
KH2PO4, 15 mM glucose, 0.7 mM EGTA, 25 mM NaHCO3) that
had been equilibrated with 95% O2/5% CO2. Then the tissue was
perfused with collagenase type I, 90 UI/ml in Krebs Henseleit con-
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taining 5 mM Ca2 at 37‡C until the liver was soft (usually 8^10 min).
The liver capsule was removed and the isolated hepatocytes were
shaken into fresh Krebs Henseleit containing 2.5 mM Ca2. Paren-
chymal cells were washed by two centrifugations at 600Ug for 5 min.
Cell viability was always higher than 95% as assessed by trypan blue
exclusion. Hepatocytes (1U107) were incubated at 37‡C with C2-cer-
amide and the di¡erent inhibitors for the time indicated in each case.
2.3. Subcellular fractionation
Hepatocytes treated with C2-ceramide and the di¡erent inhibitors
were resuspended in an ice-cold homogenization bu¡er (20 mM Tris^
HCl, pH 7.5, 10 mM NaCl, l mM PMSF, l Wg/ml aprotinin, 2 Wg/ml
leupeptin) and lysed with V50 strokes with a Potter^Elvehjem ho-
mogenizer on an ice bath. Homogenates were centrifuged at 800Ug
for 5 min at 4‡C. The pellet was used to isolate nuclei and the super-
natant was used to isolate cytosolic and particulate fractions.
The 800Ug supernatant was centrifuged at 15 000Ug for 15 min at
4‡C. The supernatant obtained was used as the non-nuclear fraction.
In some cases this fraction was centrifuged at 100 000Ug for 60 min
at 4‡C, and the supernatant obtained was used as the cytosolic frac-
tion. The pellet was resuspended in a bu¡er containing: 50 mM Tris^
HCl, pH 7.5, 0.5 mM EDTA, 0.5 mM EGTA, 1% Nonidet P-40 and
0.1% 2-mercaptoethanol and was shaken at 4‡C for 60 min and cen-
trifuged at 100 000Ug for 60 min at 4‡C. The supernatant obtained
was used as the membrane fraction as described previously [25].
The nuclear fraction was obtained by the method of Fields et al.
[26]. Brie£y, the 800Ug pellet was resuspended in STM bu¡er (50 mM
Tris^HCl, pH 7.4, 250 mM sucrose and 5 mM MgSO4) and capped
over a bu¡er containing 2.1 mM sucrose, 50 mM Tris^HCl, pH 7.4,
5 mM MgSO4 and 1% 2-mercaptoethanol. Nuclei were successively
pelleted at 70 000Ug for 60 min in an SW 28 rotor. When the nuclear
fraction was used for immunoblot analysis, the isolated nuclei were
resuspended in STM bu¡er and incubated for 60 min at 4‡C with
DNase I and RNase A (100 Wg/ml each). Nuclease-treated nuclei
were sedimented at 800Ug for 10 min and resuspended in 50 mM
Tris^HCl, pH 7.4, at 5U108 nuclei/ml. Marker enzymes were used in
conjunction with electron microscopy to ensure that the preparations
contained intact nuclei and were free of contaminating organelles, and
determination of DNA content indicated a mean reactivity of approx-
imately 20%, as described previously [27].
2.4. PKC j determination by Western blotting
Immunoblot analysis was carried out on cytosol, membrane and
nuclear fractions basically as described previously [25]. Equal amounts
of protein (100 Wg) from each fraction were separated and analyzed by
SDS^PAGE and then transferred to nitrocellulose membranes. After
blocking non-speci¢c sites with 0.1% (v/v) Tween-20 in 20 mM Tris^
base, 137 mM NaCl adjusted to pH 7.6 with 1 M HCl, containing 1%
(w/v) bovine serum albumin for 3 h at room temperature, the mem-
branes were incubated with anti-PKC j antibody overnight at 4‡C (1/
1000 dilution). After washing, the membranes were incubated for 2 h
at room temperature with horseradish peroxidase-linked secondary
antibody (1/2000 dilution in a solution containing 4% skimmed
milk). Bound antibody was detected by the enhanced chemilumines-
cence method according to the manufacturer’s (Amersham) instruc-
tions. The scanned images of autoradiograms were quanti¢ed by the
Sigmagel image program. Protein concentration was determined by
the method of Lowry et al. [28].
2.5. PI3-kinase assay
PI3-kinase was immunoprecipitated essentially as described previ-
ously [29]. Both nuclear and non-nuclear fractions were incubated
with anti-phosphotyrosine PY20 antibody (10 Wg/mg protein) over-
night at 4‡C and then with protein-A Sepharose beads for 2 h at
4‡C. Immunoprecipitates were collected by centrifugation at
10 000Ug for 5 min at 4‡C, then washed three times with Nonidet
P-40 bu¡er (20 mM Tris^HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA,
1% Nonidet P-40, 1 mM sodium vanadate and 1 mM PMSF), once
with LiCl solution (0.5 M LiCl, 0.1 M Tris^HCl, pH 7.5), once with
distilled water and once with washing bu¡er (0.1 M NaCl, 1 mM
EDTA, 20 mM Tris^HCl, pH 7.5) and, ¢nally, subjected to PI3-ki-
nase assay.
PI3-kinase activity was measured by following the PIP formation
from phosphorylation of PI with [Q-32P]ATP basically as described by
Yano et al. [29]. Brie£y, immunoprecipitates were suspended in 50 Wl
of a bu¡er containing 20 mM Tris^HCl, pH 7.5, 100 mM NaCl and
0.5 mM EGTA. Then 1 Wl of 10 mg/ml phosphatidylinositol dissolved
in dimethyl sulfoxide was added to the reaction mixture. The mixture
was preincubated at 25‡C for 10 min. [Q-32P]ATP (2.5 WCi/assay, ¢nal
concentration 10 WM) and MgCl2 (¢nal concentration 20 mM) were
added to start the reaction, and the mixture was incubated at 25‡C for
30 min. The reaction was stopped by the addition of 100 Wl of chlo-
roform, methanol, 11.6 N HCl (100:200:2). The lipid-containing or-
ganic phase was resolved on oxalate-coated thin-layer chromatogra-
phy plates (Silica Gel 60) developed in chloroform/methanol/acetic
acid/acetone/water (40:13:12:15:8 by volume) as described previously
[30]. 32P-labeled PI3P was visualized by autoradiography and the
spots were quanti¢ed by scintillation counting.
3. Results and discussion
Sphingolipid derivatives have been reported to regulate
PKC action in di¡erent cell types [6^10]. To study the possible
action of C2-ceramide on redistribution of PKC j in rat he-
patocytes, in this paper we tested the e¡ect of 35 WM C2-
ceramide on PKC j in cytosol, membrane and nuclei for dif-
ferent times. In untreated hepatocytes, PKC j was distributed
between the cytosolic (about 55%), membrane (about 35%)
and nuclear (about 10%) fractions (data not shown), and after
C2-ceramide treatment a notable increase of PKC j in nucleus
and membrane was found (Fig. 1). A maximal e¡ect was
observed after 90 min of C2-ceramide treatment, about
250% of the control value (100%). Although a translocation
from cytosol to both nucleus and membrane occurred, no
decrease of the enzyme in cytosol was observed. The di⁄culty
in detecting variations in the amount of PKC j in the cyto-
solic fraction may be explained by the high immunoreactivity
of the enzyme observed in cytosol. After C2-ceramide treat-
ment, there is likely to be an undetectable percentage of PKC
j that is translocated to nucleus and membrane as described
previously [31^33]. A discrepancy exists in the literature re-
garding whether the activation of PKC requires the translo-
cation from the cytosol to membrane. However, this phenom-
enon appears to be dependent on the type of cell and the
stimulus. A number of growth factors have been reported to
stimulate and increase the cytosolic form of PKC and, more-
over, several studies have documented that activation of PKC
may result in an increase in total cellular PKC content [34].
From our results, we cannot exclude the possibility that a
generalized increase of PKC j occurs.
Results from experiments performed at di¡erent concentra-
tions of C2-ceramide, in a range from 5 to 35 WM, indicate
that a maximal increase of PKC j is observed in nucleus at
the highest concentration tested (Fig. 1B). It must be pointed
out that higher concentrations of C2-ceramide (i.e. 50 WM)
resulted in similar changes to those observed with 35 WM
(data not shown). It has been reported that PKC j may reside
in or translocate to the nucleus, in response to mitogenic
signals, where it directly phosphorylates nuclear regulatory
proteins or can activate downstream protein kinase cascades
that modulate the gene expression [34].
PKC j activity can be stimulated by PI3-kinase with a
negligible e¡ect on other PKC isoforms [20,21]. To assess
the contribution of PI3-kinase in C2-ceramide-induced redis-
tribution of PKC j in hepatocytes, we ¢rst examined the e¡ect
of di¡erent concentrations of wortmannin, a fungal PI3-ki-
nase inhibitor, on the e¡ect evoked by C2-ceramide. As can
be seen in Fig. 2A, wortmannin, at concentrations as low as
5 nM, partially reverses the e¡ect evoked by 35 WM C2-ceram-
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ide after 90 min of treatment, in both membrane and nuclear
fractions. Higher concentrations of wortmannin totally inhibit
C2-ceramide-induced PKC j increase. Bearing in mind that
the e¡ect of wortmannin may be due to PI3-kinase inhibition,
we investigated whether inhibition of PI3-kinase by an alter-
native, unrelated compound such as LY 294002 was also able
to modify the e¡ect of C2-ceramide. As shown in Fig. 2B, LY
294002 at a concentration of 1 WM, which completely inhibits
PI3-kinase in hepatocytes [35], has also an inhibitory e¡ect on
C2-ceramide-induced PKC j increase, similar to that of wort-
mannin.
To study the involvement of PI3-kinase in C2-ceramide
actions further, we measured the PI3-kinase activity in both
nuclear and non-nuclear fractions in isolated hepatocytes. As
shown in Fig. 3A, the PI3-kinase activity, immunoprecipitated
by using anti-phosphotyrosine antibody (PY20), increased in
a time-dependent manner in the nuclear fraction, reaching a
maximum of 2.5 times that of controls after 35 WM C2-cer-
Fig. 1. E¡ect of C2-ceramide on subcellular localization of PKC j in rat hepatocytes. Isolated hepatocytes were incubated with 35 WM C2-cer-
amide for the indicated times (A) or with di¡erent C2-ceramide concentrations for 90 min (B), and cytosolic, membrane and nuclear fractions
were separated and subjected to immunoblotting with anti-PKC j antibody. The results for each experiment were normalized to the density of
PKC j of the nuclear fraction, which was arbitrary adjusted to 1.0. Basal values in arbitrary units of intensity were: 5.5, 3.5 and 1.0 for cyto-
sol, membrane and nucleus respectively. Results are expressed as percentage of control (100) and are means þ S.E.M. of three experiments.
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amide treatment for 30 min. After longer times, a smaller
increase was observed. Concomitantly, PI3-kinase activity de-
creased in the non-nuclear fraction, prepared as described
above. As can be seen in Fig. 3B, the C2-ceramide-induced
e¡ect on PI3-kinase activity was also concentration-depen-
dent. Thus, a concentration as low as 5 WM causes the in-
crease of PI3-kinase activity in the nuclear fraction (about 1.2
times that of controls). These ¢ndings indicate that the acti-
vation of PI3-kinase by C2-ceramide involves the transloca-
tion of the enzyme to the nucleus. Previous studies have in-
dicated that PI3-kinase is translocated into the nucleus after
agonist stimulation, while no nuclear association of the en-
zyme could be detected prior to the activation [36,37]. Our
¢nding supports the hypothesis that nuclear PI(3,4,5)P3, gen-
erated by PI3-kinase activity, is the driving force for PKC j
translocation to the nucleus. Nevertheless, in order to assess
whether the reported observations are speci¢c for C2-ceram-
ide, studies with other forms of ceramide are required. The
Fig. 2. E¡ect of PI3-kinase inhibition on C2-ceramide-induced PKC j translocation in rat hepatocytes. Isolated hepatocytes were incubated
with 35 WM C2-ceramide (Cer) for 90 min in the presence or absence of wortmannin (WT) (A) or LY 294002 (LY) (B), and cytosolic, mem-
brane and nuclear fractions were separated and subjected to immunoblotting with anti-PKC j antibody. Results are expressed as percentage of
control and are means þ S.E.M. of three experiments.
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fact that nuclear PI3-kinase activation is required for C2-cer-
amide-induced PKC j translocation to the nucleus may indi-
cate a link for the communication between cytosolic and nu-
clear signal pathways.
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Fig. 3. E¡ect of C2-ceramide on nuclear PI3-kinase activity in rat
hepatocytes. Isolated hepatocytes were incubated with 35 WM C2-
ceramide for di¡erent times (A) or di¡erent concentrations of C2-
ceramide for 90 min (B). The nuclear fraction was separated and
PI3-kinase activity was measured. Basal values were: 615 and 1169
cpm/mg protein for nuclear and non-nuclear fractions respectively.
Results are expressed as percentage of control (100) and are means
þ S.E.M. of three experiments.
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